

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES

3D Medicines Inc. (the “**Company**”) is pleased to announce that following an application to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Stock Exchange has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules (the “**Relevant Rules**”) to the Company.

As a result of the dis-application of the Relevant Rules, the “B” marker will no longer be affixed to the Company’s stock short name. The Company will make a further announcement in relation to the effective date of the removal of the “B” marker in due course.

REASONS FOR THE DIS-APPLICATION OF THE RELEVANT RULES

The Company is a biotechnology company which listed its ordinary shares (the “**Shares**”) on the Main Board of the Stock Exchange on December 15, 2022 pursuant to Chapter 18A of the Listing Rules.

The Company now satisfies the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules. In particular, the Company has a trading record of at least three financial years, management continuity for at least the three preceding financial years and ownership continuity and control for at least the most recent audited financial year. The Company’s market capitalization as of May 8, 2023, based on the closing price of the day, was approximately HKD16.26 billion, which is in excess of HKD4 billion as required under Rule 8.05(3) of the Listing Rules.

As stated in the annual report of the Company for the year ended December 31, 2022 published on April 28, 2023, the Company’s total revenue for the year ended December 31, 2022, being the most recent audited financial year, was approximately RMB567.4 million (equivalent to approximately HKD643.1 million), which is in excess of HKD500 million as required under Rule 8.05(3) of the Listing Rules.

Accordingly, the Company satisfies the requirements under Rule 8.05(3) of the Listing Rules and the Stock Exchange has therefore granted its approval for the application for dis-application of the Relevant Rules to the Company.

EFFECTS OF THE DIS-APPLICATION OF THE RELEVANT RULES

The dis-application of the Relevant Rules will have no effect on the existing share certificates in respect of the Company's Shares which will continue to be good evidence of legal title and be valid for trading, settlement and registration purposes and will not involve any transfer or exchange of the existing share certificates for holders of Shares. Following the dis-application of the Relevant Rules, the "B" marker will cease to be affixed to the Company's stock short name. No other changes will be made to the stock short name of the Company, the existing share certificates, the board lot size, the trading currency of the Shares and the share registrar and transfer offices of the Company following the dis-application of the Relevant Rules.

For the purpose of this announcement and for illustrative purpose only, conversions of RMB to HKD are based on the exchange rate of RMB0.88234=HKD1.00. No representation is made that any amounts in HKD or RMB can be or could have been converted at the relevant dates at the above rate, at any other rates, or at all.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, May 9, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.